FAQ: Aditxt Inc. Subsidiary Pearsanta's IRB Approval for Endometriosis Diagnostic Study

What is the Mitomic Endometriosis Test (MET)?

The Mitomic Endometriosis Test (MET) is a blood-based diagnostic designed to detect mitochondrial DNA deletions for the early detection of endometriosis, offering a non-invasive alternative to the current standard laparoscopic diagnosis.

Why is the MET study significant?

The study is significant because it could lead to the launch of a non-invasive diagnostic test for endometriosis, potentially reducing the diagnostic delays that currently impact millions of women worldwide.

How does the MET compare to current diagnostic methods?

Unlike the current standard of laparoscopic diagnosis, which is invasive, the MET offers a non-invasive approach by detecting mitochondrial DNA deletions through a blood test.

When will the MET study begin and how many participants will it involve?

The study is set to begin in May 2025 and will enroll up to 1,000 participants to compare MET results with laparoscopic diagnoses.

Who is conducting the MET study?

The study is being conducted by Pearsanta, a subsidiary of Aditxt Inc., following Institutional Review Board (IRB) approval.

What are the potential implications of the MET study?

Successful results from the study may support the launch of MET as a Laboratory Developed Test from Pearsanta’s certified lab, offering a new diagnostic tool for endometriosis.

Where can I find more information about Aditxt Inc. and its subsidiaries?

For more information about Aditxt Inc. and its subsidiaries, please visit www.Aditxt.com or the company’s newsroom at https://ibn.fm/ADTX.

What other programs does Aditxt Inc. operate?

Aditxt Inc. currently operates programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.